Luke A. Pallansch

929 citations

24 papers · 763 indexed · h-index 15

Co-authors: Robert W. Buckheit Carol Lackman-Smith Valerie Fliakas-Boltz Naijie Jing J. Sampugna Mark Keeney Erik De Clercq Mary G. Enig
Topics: HIV Research and Treatment (14 papers)HIV/AIDS drug development and treatment (11 papers)Pneumocystis jirovecii pneumonia detection and treatment (3 papers)
Cited by: Virology Infectious Diseases Microbiology
Journals: Journal of Biological Chemistry Biochemistry Analytical Biochemistry
Partner nations: United States Belgium Switzerland

In The Last Decade

Luke A. Pallansch

24 papers receiving 722 citations

Peers

Countries citing papers authored by Luke A. Pallansch

Since Specialization

Citations

This map shows the geographic impact of Luke A. Pallansch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke A. Pallansch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke A. Pallansch more than expected).

Fields of papers citing papers by Luke A. Pallansch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke A. Pallansch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke A. Pallansch. The network helps show where Luke A. Pallansch may publish in the future.

Co-authorship network of co-authors of Luke A. Pallansch

This figure shows the co-authorship network connecting the top 25 collaborators of Luke A. Pallansch. A scholar is included among the top collaborators of Luke A. Pallansch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke A. Pallansch. Luke A. Pallansch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Using a noninfectious MVM surrogate for assessing viral clearance during downstream process development 2019 ·Biotechnology Progress ·(unknown),(unknown),(unknown),(unknown),(unknown),Arun K. Dhar,Luke A. Pallansch,Matthew Dickson	7
2	Use of a noninfectious surrogate to predict minute virus of mice removal during nanofiltration 2018 ·Biotechnology Progress ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Arun K. Dhar,Luke A. Pallansch,Daniel Strauss	11
3	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent 2008 ·Antimicrobial Agents and Chemotherapy ·Roger G. Ptak,Philippe Gallay,Dirk Jochmans,Andrew P. Halestrap,Urs T. Rüegg,Luke A. Pallansch,Michael Bobardt,Marie‐Pierre de Béthune,Johan Neyts,Erik De Clercq,Jean‐Maurice Dumont,Piétro Scalfaro,Kamel Besseghir,Roland M. Wenger,Brigitte Rosenwirth	93
4	Design, Synthesis and Biological Evaluation of a Series of Thioamides as Non-Nucleoside Reverse Transcriptase Inhibitors 2007 ·Medicinal Chemistry ·Ahmed Mehanna,(unknown),Charles J. Kelley,Luke A. Pallansch	14
5	Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus andd-Amino Acid-Containing Chemokine 2007 ·Journal of Virology ·Dongxiang Liu,Navid Madani,Ying Li,Rong Cao,Won‐Tak Choi,Sameer Kawatkar,(unknown),Santosh Kumar,Chang‐Zhi Dong,Jun Wang,(unknown),(unknown),Jing An,Scott R. Wilson,Yi‐Gui Gao,Luke A. Pallansch,Joseph Sodroski,Ziwei Huang	15
6	Naturally Occurring Capsid Substitutions Render HIV-1 Cyclophilin A Independent in Human Cells and TRIM-cyclophilin-resistant in Owl Monkey Cells 2005 ·Journal of Biological Chemistry ·Udayan Chatterji,Michael Bobardt,Robyn L. Stanfield,Roger G. Ptak,Luke A. Pallansch,(unknown),(unknown),Cheryl A. Stoddart,Piétro Scalfaro,Jean‐Maurice Dumont,Kamel Besseghir,Brigitte Rosenwirth,Philippe Gallay	64
7	Potassium-Dependent Folding: A Key to Intracellular Delivery of G-Quartet Oligonucleotides as HIV Inhibitors 2002 ·Biochemistry ·Naijie Jing,Weijun Xiong,Yongli Guan,Luke A. Pallansch,Shimei Wang	33
8	Structural characterization and comparison of promoter activity of mouse and bovine interphotoreceptor retinoid-binding protein (IRBP) gene 5' flanking regions in WERI, Y79, chick retina cells, and transgenic mice 2001 ·Current Eye Research ·Diane E. Borst,Jeffrey H. Boatright,(unknown),Eva Stodůlková,Nancy A Remaley,Luke A. Pallansch,John M. Nickerson	7
9	Structure–Activity of Inhibition of HIV-1 Integrase and Virus Replication by G-quartet Oligonucleotides 2001 ·DNA and Cell Biology ·Naijie Jing,Christophe Marchand,Yongli Guan,Jie Liu,Luke A. Pallansch,Carol Lackman-Smith,Erik De Clercq,Yves Pommier	17
10	Stability-Activity Relationships of a Family of G-tetrad Forming Oligonucleotides as Potent HIV Inhibitors 2000 ·Journal of Biological Chemistry ·Naijie Jing,Erik De Clercq,Robert F. Rando,Luke A. Pallansch,Carol Lackman-Smith,Sandy Lee,Michael E. Hogan	48
11	Bovine Immunodeficiency VirustatGene: Cloning of Two Distinct cDNAs and Identification, Characterization, and Immunolocalization of thetatGene Products 1997 ·Virology ·(unknown),(unknown),(unknown),David Derse,Luke A. Pallansch,Terry Copeland,Lynn Rasmussen,Anita Mentzer,Kunio Nagashima,Gregory J. Tobin,Matthew A. Gonda	11
12	Efficacy, Pharmacokinetics, and in Vivo Antiviral Activity of UC781, a Highly Potent, Orally Bioavailable Nonnucleoside Reverse Transcriptase Inhibitor of HIV Type 1 1997 ·AIDS Research and Human Retroviruses ·Robert W. Buckheit,(unknown),Sherman F. Stinson,Valerie Fliakas-Boltz,Luke A. Pallansch,J. Alan Roberson,Walter J. Decker,(unknown),Suzanne Borgel,Carrie Bonomi,(unknown),(unknown),Louis Malspeis,John P. Bader	25
13	Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus. 1997 ·PubMed ·Sheng‐Shun Yang,Nagarajan Pattabiraman,Rick Gussio,Luke A. Pallansch,(unknown),(unknown)	2
14	Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates 1997 ·Antimicrobial Agents and Chemotherapy ·Robert W. Buckheit,M Snow,Valerie Fliakas-Boltz,(unknown),(unknown),Luke A. Pallansch,W G Brouwer,(unknown)	37
15	Isolation and Characterization of HIV-1 Isolates Resistant to Oxathiin Carboxanilide Analogues: Evaluation of Variables in the Drug Resistance Selection Process 1996 ·Antiviral chemistry & chemotherapy ·(unknown),Luke A. Pallansch,Robert W. Buckheit	5
16	cis-Acting Regulatory Elements in the Bovine Immunodeficiency Virus Long Terminal Repeat 1995 ·Virology ·(unknown),Luke A. Pallansch,Judy A. Mikovits,Carol Lackman-Smith,Francis W. Ruscetti,Matthew A. Gonda	9
17	T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1 1995 ·Antimicrobial Agents and Chemotherapy ·J O Ojwang,Robert W. Buckheit,Yves Pommier,Abhijit Mazumder,K De Vreese,José A. Esté,D. Reymen,Luke A. Pallansch,Carol Lackman-Smith,T L Wallace	93
18	Bovine immunodeficiency-like virus encodes factors which trans activate the long terminal repeat 1992 ·Journal of Virology ·Luke A. Pallansch,Carol Lackman-Smith,Matthew A. Gonda	25
19	Nuclear run-on transcription from primary embryonic lens tissue 1989 ·Developmental Biology ·Peggy S. Zelenka,Luke A. Pallansch,(unknown)	12
20	Rapid analysis of trans fatty acids on SP-2340 glass capillary columns 1982 ·Journal of Chromatography A ·J. Sampugna,Luke A. Pallansch,Mary G. Enig,Mark Keeney	61

About Luke A. Pallansch

Luke A. Pallansch is a scholar working on Virology, Infectious Diseases and Agronomy and Crop Science, having authored 24 papers that have together received 763 indexed citations. Recurring topics across this work include HIV Research and Treatment (14 papers), HIV/AIDS drug development and treatment (11 papers) and Pneumocystis jirovecii pneumonia detection and treatment (3 papers). The work is most often cited by research in Virology (347 citations), Infectious Diseases (314 citations) and Microbiology (42 citations). Luke A. Pallansch has collaborated with scholars based in United States, Belgium and Switzerland. Frequent co-authors include Robert W. Buckheit, Carol Lackman-Smith, Valerie Fliakas-Boltz, Naijie Jing, J. Sampugna, Mark Keeney, Erik De Clercq, Mary G. Enig, Peggy S. Zelenka and Jean‐Maurice Dumont. Their work appears in journals such as Journal of Biological Chemistry, Biochemistry and Analytical Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact